Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Xu, B; Saito, Y; Baumbach, A; Kelbæk, H; van, Royen, N; Zheng, M; Morel, MA; Knaapen, P; Slagboom, T; Johnson, TW; Vlachojannis, G; Arkenbout, KE; Holmvang, L; Janssens, L; Ochala, A; Brugaletta, S; Naber, CK; Anderson, R; Rittger, H; Berti, S; Barbato, E; Toth, GG; Maillard, L; Valina, C; Buszman, P; Thiele, H; Schächinger, V; Lansky, A; Wijns, W, , TARGET, AC, Investigators.
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
JACC Cardiovasc Interv. 2019; 12(17):1679-1687
Doi: 10.1016/j.jcin.2019.05.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Toth-Gayor Gabor
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove-filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. BACKGROUND: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. METHODS: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. RESULTS: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). CONCLUSIONS: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.
- Find related publications in this database (using NLM MeSH Indexing)
- Absorbable Implants - administration & dosage
- Aged - administration & dosage
- Cardiovascular Agents - administration & dosage, adverse effects
- Coronary Artery Disease - diagnostic imaging, mortality, therapy
- Coronary Thrombosis - etiology
- Drug-Eluting Stents - administration & dosage
- Dual Anti-Platelet Therapy - administration & dosage
- Europe - administration & dosage
- Everolimus - administration & dosage, adverse effects
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Percutaneous Coronary Intervention - adverse effects, instrumentation, mortality
- Polymers - chemistry
- Prospective Studies - administration & dosage
- Prosthesis Design - administration & dosage
- Risk Factors - administration & dosage
- Sirolimus - administration & dosage, adverse effects
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- clinical outcome
- drug-eluting stent
- everolimus-eluting stent
- Firehawk